Pre-clinical criteria sustaining the safe use of recombinant human erythropoietin (EPOrh);Criterios preclínicos que sustentan el uso de la eritropoyetina recombinante humana

Biotecnologia Aplicada

Volumn 22, Issue 3, 2005, Pages 173-181

  Bacardí, Dania M ^a   Cosme, Karelia ^a   Porras, Delia N ^a   Rodríguez, Elías N ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Carcinogenesis; Erythropoietin; Mutagenesis; Preclinical study; Toxicity

Indexed keywords

EID: 76749163593     PISSN: 08644551     EISSN: 10272852     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Da Silva JL, Scwartman ML, Goodman A, Levere RD, Abraham NG. Localization od erythropoietin mRNA in rats kidney by polymerase chain reaction. J Cell Biochem 1994;54:239-46.
2. Lacombe C, Da Silva JL, Bruenal P, etal. Peritubllar cell are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 1998;81:620-3.
3. Jelkmann W. Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr Pharm Biotechnol 2000;1(1):11-31.
4. Rizzo JD, Seidenfeld J, Piper M, Aronson N, Lichtin A, Littlewood TJ. Erythropoietin a paradigm for the development of practice guidelines [review]. Hematology (Am Soc Hematol Educ Program) 2001;10-30.
5. Henke M, Laszig R, Rube C, et al. Erytropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362:1255-60.
6. Miles SA, Mitsuyasu RT, Moreno J, Baldwin G, Alton NK, Souza L, Glaspy JA. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine Blood 1991; 15.77(10):2109-17.
7. Ferrario E, Ferrari L, Bidoli P, De Candis D, Del Vecchio M, De Dosso S, Buzzoni R, Bajetta E. Treatment of cancer-related anemia with epoetin alfa: a review. Cancer Treat Rev 2004;30(6):563-75.
8. Bristow A. Collaborative study fot the establishment of a biological reference preparation for erythropoietin. Pharmeuropa Special Issue 1997;BIO:97-102.
9. The Directorate for the Quality of Medicines of the Council of Europe (EDQM). Erythropoietin concentrates solution. In: European Pharmacopoeia (Fourth Edition). Strasburg: Council of Europe 2001;1123-8.
10. Food and drug administration. Good Laboratory Practice for non clinical laboratory studies. Title 21 Code of Federal Regulations, Subchapter A, Part 58.1997.
11. ICH/EMEA Preclinical safety evaluation of Biotechnology-Derived Pharmaceuticals. Step 4. (CPMP/ICH/302/95) 1997. http:\\www.EMEA.EU.int.com.
12. ICH/EMEA No-clinical safety studies for the conduct of Human clinical trials for pharmaceuticals. ICH M3 (M) (Modification of CPMP/ICH/286/95). 2000. http:\\www.EMEA.EU.int.com.
13. OECD. Guidelines for the Testing of Chemicals 425: Acute Oral Toxicity; Modified Up-and-Down Procedure. Section 4: Health Effects (Updated Guideline, adopted 20th December 2001).
14. ICH/EMEA Note for Guiadance on non-clinical local tolerance testing of medicinal products (CPMP/SWP/2145/ 00). 2000. http:\\www.EMEA.EU.int.com.
15. CECMED. Requisitos para las solicitudes de inscripción, renovación y modificación en el registro de medicamentos de uso humano. La Habana, Cuba, 2001.
16. Yamamoto Y, Sofikitis N, Miyagawa I. Effects of erythropoietin, bromocryptine and hydralazine on testicular function in rats with chronic renal failure. Andrología 1997;29(3):141-4.
17. Kokot F, Wiecek A, Grzeszczak W, Klin M. Influence of erythropoietin treatment on follitropin and lutropin response to luliberin and plasma testosterone levels in haemodialyzed patients. Nephron 1990;56(2):126-9.
18. Foresta C, Mioni R, Bordon P, Miotto D, Montini G, Varotto A. Erythropoietin stimulates testosterone production in man. J Clin Endocrinol Metab1994;78(3):753-6.
19. Kuwahara M, Takagi N, Nishitani M, Matsushita K, Ohta K, Nakamura K, Fujisaki N. Evaluation of the efficacy of recombinant human erythropoietin (rHuEPO) administration on penile erection in males undergoing hemodialysis and effect on pituitary-gonadal function. Nippon Hinyokika Gakkai Zasshi 1995; 86(4):912-8.
20. Ohls RK. Erythropoietin to prevent and treat the anemia of prematurity. Curr Opin Pediatr 1999;11(2):108-14.
21. De la Torre M, Gascon FJ, Zapatero M, et al. Prophylaxis of anemia of prematurity with erythropoietin. Case control study. An Esp Pediatr 2000;53(3):243-8.
22. Huch R, Huch A. Erythropoietin in obstetrics. Hematol Oncol Clin North Am 1994;8(5):1021-40.
23. Yajima N, Kurata Y, Imai E, Sawai T, Takeshita Y. Genotoxicity of genetic recombinant human erythropoietin in a novel test system. Mutagenesis 1993;8(3):231-6.
24. Yajima N, Kurata Y, Sawai T, Takeshita Y. Induction of micronucleated erythrocytes by recombinant human erythropoietin. Mutagenesis 1993;8(3):221-9.
25. Thews O, Kelleher DK, Vaupel P Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 2001;61(4): 1358-61.
26. Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci (USA) 2001; 98(9):5181-6.
27. Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, Selzer E, Lavey RS. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50(3):705-15.
28. Osterbor A. The role of recombinant human erythropoietin in the management of anaemic cancer patients: focus on haematological malignancies. Med Oncol 2000;17(1):S17-22.
29. Volberding P. Consensus statement: anemia in HIV infection-current trends, treatment options, and practice strategies. Anemia in HIV Working Group. Clin Ther 2000;22(9):1004-20.
30. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61(9):3561-5.
31. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int Aug 2000;58(2):647-57.
32. Erickson-Miller CL, Pelus LM, Lord KA. Signaling induced by erythropoietin and stem cell factor in UT-7/Epo cells: transient versus sustained proliferation. Stem Cells 2000;18(5):366-73.
33. Lissoni P, Rovelli F, Baiocco N, Tangini G, Fumagalli L. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone. Anticancer Res 2001;21(1B):777-9.
34. Sinor AD, Greenberg DA. Erythropoietin protects cultured cortical neurons, but not astroglia, from hypoxia and AMPA toxicity. Neurosci Lett 2000;290(3):213-5.
35. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997;76(1): 105-16.
36. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci (USA) 1998;95(8):4635-40.
37. Cerami A. Beyond erythropoiesis: novel applications for recombinant human erythropoietin. Semin Hematol 2001;38(3 Suppl 7):33-9.
38. Siren AL, Ehrenreich H. Erythropoietin: a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci 2001; 251(4):179-84.
39. Ramírez G, Bittle PA, Sanders H, Bercu BB. Hypothalamo-hypophyseal thyroid and gonadal function before and after erythropoietin therapy in dialysis patients. J Clin Endocrinol Metab 1992; 74(3):517-24.